<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Quince Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/quince-therapeutics-inc</link>
<description>Latest news and press releases for Quince Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/quince-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b46978dffbe2df113209.webp</url>
<title>Quince Therapeutics, Inc.</title>
<link>https://6ix.com/company/quince-therapeutics-inc</link>
</image>
<item>
<title>Quince Therapeutics Settles Approximately $16.4 Million of Debt</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-settles-approximately-dollar164-million-of-debt</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-settles-approximately-dollar164-million-of-debt</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company’s</description>
</item>
<item>
<title>Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-engages-lifesci-capital-210500796</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-engages-lifesci-capital-210500796</guid>
<pubDate>Mon, 09 Feb 2026 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., February 09, 2026--Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value.</description>
</item>
<item>
<title>Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-topline-results-201000292</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-topline-results-201000292</guid>
<pubDate>Thu, 29 Jan 2026 20:10:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., January 29, 2026--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T).</description>
</item>
<item>
<title>Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-presents-safety-data-210500987</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-presents-safety-data-210500987</guid>
<pubDate>Wed, 28 Jan 2026 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., January 28, 2026--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association 2026 Annual Meeting taking place in Glasgow, Scotland January 28-30, 2026.</description>
</item>
<item>
<title>Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-last-patient-130000551</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-last-patient-130000551</guid>
<pubDate>Mon, 15 Dec 2025 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., December 15, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company’s pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in pati</description>
</item>
<item>
<title>Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-publication-edsp-210500793</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-publication-edsp-210500793</guid>
<pubDate>Wed, 10 Dec 2025 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., December 10, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red blood cells), in pulmonary and inflammatory bowel disorders (IBD) in the scientific journal Frontiers</description>
</item>
<item>
<title>Quince Therapeutics to Participate at Investor Events in December 2025</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-participate-investor-events-130000797</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-participate-investor-events-130000797</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., November 24, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that senior management will participate at three investor events in December 2025:</description>
</item>
<item>
<title>Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-provides-business-reports-210500740</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-provides-business-reports-210500740</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., November 12, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-positive-idsmb-210500481</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-positive-idsmb-210500481</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., November 10, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the positive outcome of its pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB) for the company’s ongoing pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical tri</description>
</item>
<item>
<title>Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-presents-data-patient-200500423</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-presents-data-patient-200500423</guid>
<pubDate>Thu, 09 Oct 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., October 09, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation of patient-reported walking capacity in children with Ataxia-Telangiectasia (A-T) at the 54th Child Neurology Society (CNS) Annual Meeting. The objective of the data analysis was to describe the pattern of age-related walking capacity loss</description>
</item>
<item>
<title>Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-cpt-pharmacometrics-200500011</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-cpt-pharmacometrics-200500011</guid>
<pubDate>Thu, 25 Sep 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., September 25, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of an advanced population pharmacokinetic (PK) modeling study of pediatric patients with Ataxia-Telangiectasia (A-T) and healthy adults treated with its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red</description>
</item>
<item>
<title>Quince Therapeutics to Host Virtual Investor Day on October 2, 2025</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-host-virtual-investor-200500191</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-host-virtual-investor-200500191</guid>
<pubDate>Thu, 11 Sep 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., September 11, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that it will host a virtual Investor Day on Thursday, October 2, 2025, from 10:00 a.m. and 12:00 p.m. Eastern Time. Quince’s virtual Investor Day will feature presentations from the company’s leadership team who will share the latest clinical development and cor</description>
</item>
<item>
<title>Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-present-h-c-200500741</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-present-h-c-200500741</guid>
<pubDate>Tue, 02 Sep 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., September 02, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at the H.C. Wainwright 27th Annual Global Investment Conference. Access to the company’s presentation will be available on Friday, September 5, 2025 beginning at 7</description>
</item>
<item>
<title>Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-provides-business-reports-200500260</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-provides-business-reports-200500260</guid>
<pubDate>Mon, 11 Aug 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., August 11, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the second quarter ended June 30, 2025.</description>
</item>
<item>
<title>Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-selects-option-care-120000524</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-selects-option-care-120000524</guid>
<pubDate>Thu, 07 Aug 2025 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. & BANNOCKBURN, Ill., August 07, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that it has formed a strategic relationship with Option Care Health, Inc. (Nasdaq: OPCH), the nation’s largest independent provider of home and ambulatory infusion services, to support the commercial development and efficient launch of Quince’s</description>
</item>
<item>
<title>Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-completes-enrollment-pivotal-120000869</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-completes-enrollment-pivotal-120000869</guid>
<pubDate>Wed, 16 Jul 2025 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 16, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the company has completed enrollment in its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial to evaluate its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Telang</description>
</item>
<item>
<title>Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-appoints-leading-immunologist-200500558</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-appoints-leading-immunologist-200500558</guid>
<pubDate>Thu, 10 Jul 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 10, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company’s Scientific Advisory Board (SAB). Dr.</description>
</item>
<item>
<title>Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-participate-t-society-200500345</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-participate-t-society-200500345</guid>
<pubDate>Wed, 25 Jun 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., June 25, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced its participation at the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society, a leading Ataxia-Telangiectasia (A-T) patient advocacy group based in the United Kingdom. Taking place June 25-27, 2025 at Loughborough University in the U.K., key o</description>
</item>
<item>
<title>Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-closing-22-200500676</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-closing-22-200500676</guid>
<pubDate>Wed, 18 Jun 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., June 18, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX) ("Quince" or the "Company"), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the closing of its previously announced sale and issuance to certain institutional and accredited investors, of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ("Warrants") that resulted in appro</description>
</item>
<item>
<title>Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities</title>
<link>https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-pricing-22-211500118</link>
<guid isPermaLink="true">https://6ix.com/company/quince-therapeutics-inc/news/quince-therapeutics-announces-pricing-22-211500118</guid>
<pubDate>Thu, 12 Jun 2025 21:15:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., June 12, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX) ("Quince" or the "Company"), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ("Warrants") tha</description>
</item>
</channel>
</rss>